Fragility of Evidence for the Efficacy of Anti-Fracture Medications - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessing the Vulnerability of Evidence Supporting Anti-Fracture Treatment Efficacy

  • By

  • Nick Tran

  • Thach S Tran

  • Tuan V Nguyen

  • June 9, 2025

Share

  • 1

    The study analyzed 27 phase 3/4 RCTs to assess the fragility of evidence supporting anti-fracture treatment efficacy.

  • 2

    The median Fragility Index (FI) was 9, indicating that adding 9 patients could negate the evidence of anti-fracture efficacy.

  • 3

    In 60% of analyses, the number of participants lost to follow-up exceeded the corresponding FI, highlighting evidence fragility.

  • 4

    Romosozumab showed the most robust evidence for anti-fracture efficacy, while denosumab and calcium/vitamin D had the least.

  • 5

    The findings suggest incorporating FI and Fragility Quotient into clinical guidelines and risk communication for osteoporosis management.

Original Source(s)

Fragility of Evidence for the Efficacy of Anti-Fracture Medications

  • by Nick Tran, Thach S Tran, Tuan V Nguyen

  • June 9, 2025

Related Content

Organ Damage, BMI Linked to Fatigue in SLE

Cross-sectional study suggests fatigue is associated with damage accrual and body mass, not disease activity

Higher Steroid Exposure Linked to Systemic Adverse Events in CRSwNP

Higher annual oral corticosteroid exposure was associated with greater odds of systemic adverse events, with avascular bone necrosis and pneumonia showing dose-dependent associations with cumulative dose and osteoporosis associated with longer annual exposure duration.

Bone Health and Fracture Prevention for Orthopedic Referrals

Baptist Health Orthopedic Care offers a Bone Health and Fracture Prevention Program for patients at increased risk of fracture who may benefit from early evaluation and treatment.

  • April 16, 2026

  • 2 min